Gene · 84444
Papers2,742
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
361 to 380 of 2,742
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| A novel methionine metabolism-related signature predicts prognosis and immunotherapy response in lung adenocarcinoma. | Aging (Albany NY) | 2023 | 37179124 | PubTator, text mining | PubMed |
| Profiling and integrated analysis of transcriptional addiction gene expression and prognostic value in hepatocellular carcinoma. | Aging (Albany NY) | 2023 | 37171044 | PubTator, text mining | PubMed |
| Multimodal perturbation analyses of cyclin-dependent kinases reveal a network of synthetic lethalities associated with cell-cycle regulation and transcriptional regulation. | Sci Rep | 2023 | 37169829 | PubTator, text mining | PubMed |
| Inhibition of CXorf56 promotes PARP inhibitor-induced cytotoxicity in triple-negative breast cancer. | NPJ Breast Cancer | 2023 | 37156759 | PubTator, text mining | PubMed |
| Transcriptomic analysis of feeder-free culture system for maintaining naïve-state pluripotency in human pluripotent stem cells. | Stem Cell Investig | 2023 | 37155477 | PubTator, text mining | PubMed |
| Development of multifunctional synthetic nucleosomes to interrogate chromatin-mediated protein interactions. | Sci Adv | 2023 | 37134166 | PubTator, text mining | PubMed |
| Ecological niches for colorectal cancer stem cell survival and thrival. | Front Oncol | 2023 | 37124519 | PubTator, text mining | PubMed |
| The role of the genomic mutation signature and tumor mutation burden on relapse risk prediction in head and neck squamous cell carcinoma after concurrent chemoradiotherapy. | Exp Mol Med | 2023 | 37121970 | PubTator, text mining | PubMed |
| An Update of Epigenetic Drugs for the Treatment of Cancers and Brain Diseases: A Comprehensive Review. | Genes (Basel) | 2023 | 37107631 | PubTator, text mining | PubMed |
| Palbociclib in Acute Leukemias With KMT2A-rearrangement: Results of AMLSG 23-14 Trial. | Hemasphere | 2023 | 37101762 | PubTator, text mining | PubMed |
| DOT1L regulates chromatin reorganization and gene expression during sperm differentiation. | EMBO Rep | 2023 | 37099396 | PubTator, text mining | PubMed |
| Identification of biomarkers, pathways, and potential therapeutic targets for heart failure using next-generation sequencing data and bioinformatics analysis. | Ther Adv Cardiovasc Dis | 2023 | 37092838 | PubTator, text mining | PubMed |
| Multi-omics analysis of the Indian ovarian cancer cohort revealed histotype-specific mutation and gene expression patterns. | Front Genet | 2023 | 37091785 | PubTator, text mining | PubMed |
| A novel role of DOT1L in kidney diseases. | Mol Biol Rep | 2023 | 37085741 | PubTator, text mining | PubMed |
| Comparative Study of Adenosine Analogs as Inhibitors of Protein Arginine Methyltransferases and a Clostridioides difficile-Specific DNA Adenine Methyltransferase. | ACS Chem Biol | 2023 | 37082867 | PubTator, text mining | PubMed |
| DOT-1.1 (DOT1L) deficiency in C. elegans leads to small RNA-dependent gene activation. | BBA Adv | 2023 | 37082252 | PubTator, text mining | PubMed |
| O-GlcNAcylated LARP1 positively regulated by circCLNS1A facilitates hepatoblastoma progression through DKK4/β-catenin signalling. | Clin Transl Med | 2023 | 37070251 | PubTator, text mining | PubMed |
| Mechanisms involved in cancer stem cell resistance in head and neck squamous cell carcinoma. | Cancer Drug Resist | 2023 | 37065869 | PubTator, text mining | PubMed |
| Targeting of epigenetic co-dependencies enhances anti-AML efficacy of Menin inhibitor in AML with MLL1-r or mutant NPM1. | Blood Cancer J | 2023 | 37055414 | PubTator, text mining | PubMed |
| Significance of RB Loss in Unlocking Phenotypic Plasticity in Advanced Cancers. | Mol Cancer Res | 2023 | 37052520 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/84444/papers?page=19